The Annals Visit the NEW pharmaCE.com
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 25 May 2010, www.theannals.com, DOI 10.1345/aph.1P017.
 The Annals of Pharmacotherapy: Vol. 44, No. 7, pp. 1314-1318. DOI 10.1345/aph.1P017
© 2010 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Google Scholar
Right arrow Articles by Yancey, A. M.
Right arrow Articles by Forinash, A. B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yancey, A. M.
Right arrow Articles by Forinash, A. B.

DRUG INFORMATION ROUNDS

The Prophylactic Role for the Human Papillomavirus Quadrivalent Vaccine in Males

Abigail M Yancey, PharmD BCPS

Assistant Professor of Pharmacy Practice, Department of Pharmacy Practice, St. Louis College of Pharmacy, St. Louis, MO

Jamie M Pitlick, PharmD BCPS

Assistant Professor of Pharmacy Practice, Department of Pharmacy Practice, St. Louis College of Pharmacy

Alicia B Forinash, PharmD BCPS CCD

Associate Professor of Pharmacy Practice, Department of Pharmacy Practice, St. Louis College of Pharmacy

Reprints: Dr. Yancey, Department of Pharmacy Practice, St. Louis College of Pharmacy, 4588 Parkview Place, St. Louis, MO 63110, fax 314/446-8500, ayancey{at}stlcop.edu

OBJECTIVE: To determine the role of human papillomavirus (HPV) quadrivalent vaccine in males.

DATA SOURCE: PubMed (1966–March 2010) was searched using the terms human papillomavirus, human papillomavirus vaccine, quadrivalent, males, cancer, and genital warts. Reference citations were reviewed for relevant information.

STUDY SELECTION AND DATA EXTRACTION: All studies including humans and published in English with data describing HPV quadrivalent vaccine administration in males were evaluated.

DATA SYNTHESIS: The HPV quadrivalent vaccine is currently recommended in females, but its role in males is still being defined. Three clinical trials evaluated the immunogenicity and tolerability of the vaccine in more than 1100 males 9–26 years of age. Greater than 99.5% of males seroconverted for HPV 6, 11, 16, and 18 at 1 month post-completion and titers were found to be numerically higher than those in females 16–26 years old. One study found that immune response persisted in >92.5% of males at 1 year. The results show high efficacy against detection of new anogenital lesions in males 29 months after receiving the quadrivalent HPV vaccine. In addition, the quadrivalent HPV vaccine appears to be well tolerated, with the most common adverse effects being syncope, fever, local site reactions, dizziness, nausea, and headache.

CONCLUSIONS: The HPV quadrivalent vaccine appears to be safe and induces an effective immune response in males. It may also decrease the incidence of anogenital and penile cancer, although current data are limited in number and duration of follow-up. Further analysis of the long-term immunogenicity and effects on HPV-associated complications is needed.

Key Words: anogenital cancer, genital warts, human papillomavirus, males, quadrivalent vaccine

Published Online, May 25, 2010. www.theannals.com, DOI 10.1345/aph.1P017




homecopy help contact us subscription past issues search current issue
Copyright © 2010 by Harvey Whitney Books Company.